Procedural results from the RIBS V trial presented at TCT 2013
Good outcomes with both drug-eluting stents and drug-eluting balloons in treating patients with bare metal stent restenosis
Contact information: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Procedural results from the RIBS V trial presented at TCT 2013 Good outcomes with both drug-eluting stents and drug-eluting balloons in treating patients with bare metal stent restenosis SAN FRANCISCO, CA – October 30, 2013 – A clinical trial comparing the use of drug-eluting stents (DES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from bare metal stents found that both techniques yielded positive long term outcomes. Findings from the RIBS V trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Treatment of patients with in-stent restenosis (ISR) remains a challenge. Drug-eluting balloons (DEB) have demonstrated effectiveness in patients with bare metal stent (BMS) ISR. However, the relative value of DEB versus new generation DES has not been measured.
In RIBS V, patients presenting with BMS ISR (>50 percent diameter stenosis) and angina or objective evidence of ischemia were eligible. Patients with very diffuse ISR (>30 mm), total occlusions or ISR in small vessels ( END
jromero@crf.org
Cardiovascular Research Foundation
Procedural results from the RIBS V trial presented at TCT 2013 Good outcomes with both drug-eluting stents and drug-eluting balloons in treating patients with bare metal stent restenosis SAN FRANCISCO, CA – October 30, 2013 – A clinical trial comparing the use of drug-eluting stents (DES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from bare metal stents found that both techniques yielded positive long term outcomes. Findings from the RIBS V trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Treatment of patients with in-stent restenosis (ISR) remains a challenge. Drug-eluting balloons (DEB) have demonstrated effectiveness in patients with bare metal stent (BMS) ISR. However, the relative value of DEB versus new generation DES has not been measured.
In RIBS V, patients presenting with BMS ISR (>50 percent diameter stenosis) and angina or objective evidence of ischemia were eligible. Patients with very diffuse ISR (>30 mm), total occlusions or ISR in small vessels ( END